Sarcopenia’s Prognostic Impact on Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

Background: Although sarcopenia has been reported to predict survival in cancer patients, its impact on patients who received immune checkpoint inhibitors (ICIs) has not been thoroughly investigated. This systematic review aimed to assess the long-term oncologic impact of sarcopenia on patients who...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Donggun Lee, Na Won Kim, Jong Yeob Kim, Joo Hyung Lee, Ji Hyun Noh, Haejun Lee, Jin Woon Jeong, Seungeun Lee, Jeonghyun Kang
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	sarcopenia immune checkpoint inhibitors hazard ratio overall survival progression-free survival Medicine R
Acceso en línea:	https://doaj.org/article/6bf8c5a6f8074590bcf0dddbd775042c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6bf8c5a6f8074590bcf0dddbd775042c
record_format	dspace
spelling	oai:doaj.org-article:6bf8c5a6f8074590bcf0dddbd775042c2021-11-25T18:01:48ZSarcopenia’s Prognostic Impact on Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis10.3390/jcm102253292077-0383https://doaj.org/article/6bf8c5a6f8074590bcf0dddbd775042c2021-11-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/22/5329https://doaj.org/toc/2077-0383Background: Although sarcopenia has been reported to predict survival in cancer patients, its impact on patients who received immune checkpoint inhibitors (ICIs) has not been thoroughly investigated. This systematic review aimed to assess the long-term oncologic impact of sarcopenia on patients who received ICIs. Methods: A systematic review of studies indexed in the PubMed, Embase, and Cochrane databases, up to April 1, 2021, was conducted. Studies that reported hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) based on sarcopenia in patients treated with ICIs were included. The inverse variance method was used with a random-effects model for data analysis. Results: A total of 1284 patients from 14 studies were included. Among the patients who received ICIs, patients with sarcopenia had a significant increase in overall mortality compared to patients without sarcopenia in univariate analyses (HR = 1.66, 95% CI = 1.20–2.29, <i>p</i> = 0.002) and in adjusted HRs (HR = 1.55, 95% CI = 1.15–2.10, <i>p</i> = 0.004). The same results were obtained for PFS by both univariate analysis (HR = 1.75, 95% CI = 1.37–2.23, <i>p</i> < 0.001) and adjusted HRs (HR = 1.63, 95% CI 1.28–2.09, <i>p</i> < 0.001). Conclusions: Sarcopenia appears to be an effective biomarker for predicting long-term oncologic outcomes in patients receiving ICI therapy and hence plays an important role when making treatment decisions. However, the fundamental role of this association with survival should be further investigated in large cohorts and clinical trials.Donggun LeeNa Won KimJong Yeob KimJoo Hyung LeeJi Hyun NohHaejun LeeJin Woon JeongSeungeun LeeJeonghyun KangMDPI AGarticlesarcopeniaimmune checkpoint inhibitorshazard ratiooverall survivalprogression-free survivalMedicineRENJournal of Clinical Medicine, Vol 10, Iss 5329, p 5329 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	sarcopenia immune checkpoint inhibitors hazard ratio overall survival progression-free survival Medicine R
spellingShingle	sarcopenia immune checkpoint inhibitors hazard ratio overall survival progression-free survival Medicine R Donggun Lee Na Won Kim Jong Yeob Kim Joo Hyung Lee Ji Hyun Noh Haejun Lee Jin Woon Jeong Seungeun Lee Jeonghyun Kang Sarcopenia’s Prognostic Impact on Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
description	Background: Although sarcopenia has been reported to predict survival in cancer patients, its impact on patients who received immune checkpoint inhibitors (ICIs) has not been thoroughly investigated. This systematic review aimed to assess the long-term oncologic impact of sarcopenia on patients who received ICIs. Methods: A systematic review of studies indexed in the PubMed, Embase, and Cochrane databases, up to April 1, 2021, was conducted. Studies that reported hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) based on sarcopenia in patients treated with ICIs were included. The inverse variance method was used with a random-effects model for data analysis. Results: A total of 1284 patients from 14 studies were included. Among the patients who received ICIs, patients with sarcopenia had a significant increase in overall mortality compared to patients without sarcopenia in univariate analyses (HR = 1.66, 95% CI = 1.20–2.29, <i>p</i> = 0.002) and in adjusted HRs (HR = 1.55, 95% CI = 1.15–2.10, <i>p</i> = 0.004). The same results were obtained for PFS by both univariate analysis (HR = 1.75, 95% CI = 1.37–2.23, <i>p</i> < 0.001) and adjusted HRs (HR = 1.63, 95% CI 1.28–2.09, <i>p</i> < 0.001). Conclusions: Sarcopenia appears to be an effective biomarker for predicting long-term oncologic outcomes in patients receiving ICI therapy and hence plays an important role when making treatment decisions. However, the fundamental role of this association with survival should be further investigated in large cohorts and clinical trials.
format	article
author	Donggun Lee Na Won Kim Jong Yeob Kim Joo Hyung Lee Ji Hyun Noh Haejun Lee Jin Woon Jeong Seungeun Lee Jeonghyun Kang
author_facet	Donggun Lee Na Won Kim Jong Yeob Kim Joo Hyung Lee Ji Hyun Noh Haejun Lee Jin Woon Jeong Seungeun Lee Jeonghyun Kang
author_sort	Donggun Lee
title	Sarcopenia’s Prognostic Impact on Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
title_short	Sarcopenia’s Prognostic Impact on Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
title_full	Sarcopenia’s Prognostic Impact on Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
title_fullStr	Sarcopenia’s Prognostic Impact on Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
title_full_unstemmed	Sarcopenia’s Prognostic Impact on Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
title_sort	sarcopenia’s prognostic impact on patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/6bf8c5a6f8074590bcf0dddbd775042c
work_keys_str_mv	AT donggunlee sarcopeniasprognosticimpactonpatientstreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis AT nawonkim sarcopeniasprognosticimpactonpatientstreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis AT jongyeobkim sarcopeniasprognosticimpactonpatientstreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis AT joohyunglee sarcopeniasprognosticimpactonpatientstreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis AT jihyunnoh sarcopeniasprognosticimpactonpatientstreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis AT haejunlee sarcopeniasprognosticimpactonpatientstreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis AT jinwoonjeong sarcopeniasprognosticimpactonpatientstreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis AT seungeunlee sarcopeniasprognosticimpactonpatientstreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis AT jeonghyunkang sarcopeniasprognosticimpactonpatientstreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis
_version_	1718411684219977728

Sarcopenia’s Prognostic Impact on Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

Ejemplares similares